Nomenclature: NMU2 receptor

Family: Neuromedin U receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

Contents

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 412 5q33.1 NMUR2 neuromedin U receptor 2 4,18,37,41
Mouse 7 395 11 B1.3 Nmur2 neuromedin U receptor 2 9
Rat 7 395 10q22 Nmur2 neuromedin U receptor 2 18
Gene and Protein Information Comments
For human NMU2, sequences encoding both 412 and 415 amino acids have been reported as a consequence of the presence of two potential translation initiation sites. It is unclear which form is expressed physiologically, although there is circumstantial evidence to favour the shorter form [4].
There is evidence for the existence of receptor haplotypes [3].
Previous and Unofficial Names
Names References
FM-4 18
FM4 46
SNORF72 37
G-protein coupled receptor TGR-1
G-protein-coupled receptor FM-4
neuromedin U receptor 2
NMU-R2 41
TGR-1 17
NMU2R
Database Links
Ensembl Gene
Entrez Gene
GPCRDB
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
OMIM
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Natural/Endogenous Ligands
neuromedin S-33 {Sp: Human}
neuromedin S-36 {Sp: Mouse} , neuromedin S-36 {Sp: Rat}
neuromedin U-23 {Sp: Rat}
neuromedin U-25 {Sp: Human}
Agonists
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[125I]neuromedin U-25 (human) Hs Agonist 9.8 pKd 1,5
pKd 9.8 [1,5]
[125I]neuromedin U-23 (rat) Hs Agonist 9.1 pKd 37
pKd 9.1 [37]
[125I]neuromedin U-8 (pig) Hs Agonist 9.1 pKd 37
pKd 9.1 [37]
neuromedin U-25 {Sp: Pig} Hs Agonist 9.9 pKi 1
pKi 9.9 [1]
neuromedin U-23 {Sp: Rat} Hs Agonist 9.7 pKi 1
pKi 9.7 [1]
neuromedin U-25 {Sp: Human} Hs Agonist 9.6 pKi 1
pKi 9.6 [1]
neuromedin U-8 {Sp: Pig} Hs Agonist 9.3 pKi 1
pKi 9.3 [1]
neuromedin U-8 {Sp: Dog} Hs Agonist 8.1 pKi 1
pKi 8.1 [1]
neuromedin S-33 {Sp: Human} Hs Full agonist 10.0 pEC50 28
pEC50 10.0 [28]
neuromedin U-8 {Sp: Pig} Hs Full agonist 8.5 – 9.5 pEC50 1,18,37
pEC50 8.5 – 9.5 [1,18,37]
neuromedin U-23 {Sp: Rat} Hs Full agonist 8.5 – 9.3 pEC50 1,18,37
pEC50 8.5 – 9.3 [1,18,37]
neuromedin U-25 {Sp: Human} Hs Full agonist 8.4 – 9.4 pEC50 1,5,18,37
pEC50 8.4 – 9.4 [1,5,18,37]
neuromedin U-25 {Sp: Pig} Hs Full agonist 8.6 – 9.0 pEC50 1,18,37
pEC50 8.6 – 9.0 [1,18,37]
neuromedin S-33 {Sp: Human} Hs Agonist 9.2 pIC50 28
pIC50 9.2 [28]
Agonist Comments
1) pIC50 for neuromedin S is determined against 50pM [125I-Tyr0]-neuromedin S
2) Agonism and pEC50 values are based on Ca2+ signaling by recombinant receptors expressed in cell lines.
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
R-PSOP Hs Antagonist 7.04 pKB 27
pKB 7.04 (KB 9.2x10-8 M) [27]
Primary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
Comments:  Coupling to Gi/G0 G proteins has been identified as evidenced by inhibition of forskolin-induced cAMP accumulation [1,5,17,19].
References:  1,5,37,41-42
Tissue Distribution
Peripherally: in testis and lung.
Centrally: in spinal cord, hippocampus, medulla oblongata, pontine reticular formation, thalamus and hypothalamus and cortex.
Also found to be overexpressed in pancreatic ductal adenocarcinoma and in metastatic tissues.
Species:  Human
Technique:  Northern blot, quantitative PCR, in situ hybridization
References:  18,24,37,41
A similar pattern to that of human:
Expression in medulla, spinal cord, hypothalamus, thalamus, midbrain, and pons. More specifically in the hypothalamus in the paraventricular nucleus (PVN), the wall of the third ventricle, arcuate nucleus in dispersed and punctuate manner, dorsal and lateral arcuate nucleus around the periphery of the ventromedial hypothalamus (VMH).
Species:  Mouse
Technique:  Northern blot, quantitative PCR, in situ hybridization
References:  9,12
A similar pattern to that of human:
Expression in hypothalamus, hippocampus and spinal cord. More specifically in the hypothalamus in the paraventricular nucleus (PVN), the wall of the third ventricle, the mediopostal region of the arcuate, and in the CA1 region of the hippocampus, medulla oblongata and striatum. Greatest expression in the uterus and ovary.
Species:  Rat
Technique:  Northern blot, in situ hybridization, quantitative PCR
References:  7,10,12-13,17-18
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Cells transfected with NMU2.
Species:  Mouse
Tissue:  HEK-293 cells.
Response measured:  Increase in intracellular calcium.
References:  9
Cells transfected with NMU2.
Species:  Human
Tissue:  HEK-293, CHO and COS-7 cells.
Response measured:  Increase in intracellular calcium, inositol phosphate generation, inhibition of forskolin-stimulated cAMP generation, ERK activation, G-protein activation.
References:  1,5,17-18,37,41
Physiological Functions Comments
Evidence across species (human, rat, mouse) for involvement in a range of patho-physiological aspects including:
Inhibition of food intake and increase energy expenditure [2,12,15-16,18,20-21,23,25-26,31,33,35,47,50].
Stimulation of stress response and hypothalamic-pituitary-adrenal axis [14,18,22,34,43,45,47,51].
Regulation of reproductive system hormones [8,32,34,36,39,46,48].
Pro-nociceptive effect [6,30,44,49-50].
Inhibition of bone formation and remodeling [38,40].
Regulation of circadian rhythm [11,28-30].
Pancreatic cancer [24].
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Nmur2m1Hzg Nmur2m1Hzg/Nmur2m1Hzg
involves: 129/Sv * 129S1/SvImJ * C57BL/6
MGI:2441765  MP:0005449 abnormal food intake PMID: 17030627 
Nmur2m1Hzg Nmur2m1Hzg/Nmur2m1Hzg
involves: 129/Sv * 129S1/SvImJ * C57BL/6
MGI:2441765  MP:0001970 abnormal pain threshold PMID: 17030627 
Nmur2tm1Dgen Nmur2tm1Dgen/Nmur2tm1Dgen
B6N.Cg-Nmur2
MGI:2441765  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 19324999 
Nmur2tm1.1Eege Nmur2tm1.1Eege/Nmur2tm1.1Eege
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:2441765  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 19584200 
Nmur2tm1Dgen Nmur2tm1Dgen/Nmur2tm1Dgen
B6N.Cg-Nmur2
MGI:2441765  MP:0001262 decreased body weight PMID: 19324999 
Nmur2tm1Dgen Nmur2tm1Dgen/Nmur2tm1Dgen
B6N.Cg-Nmur2
MGI:2441765  MP:0005560 decreased circulating glucose level PMID: 19324999 
Nmur2tm1Dgen Nmur2tm1Dgen/Nmur2tm1Dgen
B6N.Cg-Nmur2
MGI:2441765  MP:0005668 decreased circulating leptin level PMID: 19324999 
Nmur2m1Hzg Nmur2m1Hzg/Nmur2m1Hzg
involves: 129/Sv * 129S1/SvImJ * C57BL/6
MGI:2441765  MP:0003910 decreased eating behavior PMID: 17030627 
Nmur2tm1Dgen Nmur2tm1Dgen/Nmur2tm1Dgen
B6N.Cg-Nmur2
MGI:2441765  MP:0003910 decreased eating behavior PMID: 19324999 
Nmur2m1Hzg Nmur2m1Hzg/Nmur2m1Hzg
involves: 129/Sv * 129S1/SvImJ * C57BL/6
MGI:2441765  MP:0001442 decreased grooming behavior PMID: 17030627 
Nmur2tm1Dgen Nmur2tm1Dgen/Nmur2tm1Dgen
B6N.Cg-Nmur2
MGI:2441765  MP:0003961 decreased lean body mass PMID: 19324999 
Nmur2tm1Dgen Nmur2tm1Dgen/Nmur2tm1Dgen
B6N.Cg-Nmur2
MGI:2441765  MP:0010025 decreased total body fat amount PMID: 19324999 
Nmur2tm1Rtor Nmur2tm1Rtor/Nmur2tm1Rtor
involves: 129S1/Sv * C57BL/6NTac
MGI:2441765  MP:0008531 increased chemical nociceptive threshold PMID: 17379411 
Nmur2tm1Dgen Nmur2tm1Dgen/Nmur2tm1Dgen
B6N.Cg-Nmur2
MGI:2441765  MP:0005659 increased resistance to diet-induced obesity PMID: 19324999 
Nmur2tm1.1Eege Nmur2tm1.1Eege/Nmur2tm1.1Eege
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:2441765  MP:0005658 increased susceptibility to diet-induced obesity PMID: 19584200 
Nmur2tm1.1Eege Nmur2tm1.1Eege/Nmur2tm1.1Eege
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:2441765  MP:0005455 increased susceptibility to weight gain PMID: 19584200 
Nmur2m1Hzg Nmur2m1Hzg/Nmur2m1Hzg
involves: 129/Sv * 129S1/SvImJ * C57BL/6
MGI:2441765  MP:0001973 increased thermal nociceptive threshold PMID: 17030627 
Nmur1tm1Rtor|Nmur2tm1Rtor Nmur1tm1Rtor/Nmur1tm1Rtor,Nmur2tm1Rtor/Nmur2tm1Rtor
involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6NCr * C57BL/6NTac
MGI:1341898  MGI:2441765  MP:0001973 increased thermal nociceptive threshold PMID: 17379411 
Nmur2tm1Rtor Nmur2tm1Rtor/Nmur2tm1Rtor
involves: 129S1/Sv * C57BL/6NTac
MGI:2441765  MP:0001973 increased thermal nociceptive threshold PMID: 17379411 
Nmur2tm1.1Eege Nmur2tm1.1Eege/Nmur2tm1.1Eege
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:2441765  MP:0010024 increased total body fat amount PMID: 19584200 
Nmur2tm1Dgen Nmur2tm1Dgen/Nmur2tm1Dgen
B6N.Cg-Nmur2
MGI:2441765  MP:0008489 postnatal slow weight gain PMID: 19324999 

REFERENCES

1. Aiyar N, Disa J, Foley JJ, Buckley PT, Wixted WE, Pullen M, Shabon U, Dul E, Szekeres PG, Elshourbagy NA, Sarau HM, Appelbaum E, Bolaky J. (2004) Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells. Pharmacology72: 33-41. [PMID:15292653]

2. Bechtold DA, Ivanov TR, Luckman SM. (2009) Appetite-modifying actions of pro-neuromedin U-derived peptides. Am. J. Physiol. Endocrinol. Metab.297 (2): E545-51. [PMID:19531638]

3. Bhattacharyya S, Luan J, Farooqi IS, Keogh J, Montague C, Brennand J, Jorde L, Wareham NJ, O'Rahilly S. (2004) Studies of the neuromedin U-2 receptor gene in human obesity: evidence for the existence of two ancestral forms of the receptor. J. Endocrinol.183 (1): 115-20. [PMID:15525579]

4. Brighton PJ, Szekeres PG, Willars GB. (2004) Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol. Rev.56 (2): 231-48. [PMID:15169928]

5. Brighton PJ, Szekeres PG, Wise A, Willars GB. (2004) Signaling and ligand binding by recombinant neuromedin U receptors: evidence for dual coupling to Galphaq/11 and Galphai and an irreversible ligand-receptor interaction. Mol. Pharmacol.66 (6): 1544-56. [PMID:15331768]

6. Cao CQ, Yu XH, Dray A, Filosa A, Perkins MN. (2003) A pro-nociceptive role of neuromedin U in adult mice. Pain104: 609-616. [PMID:12927633]

7. Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Habata Y, Hinuma S, Onda H, Nishimura O, Fujino M. (2000) Identification of neuromedin U as the cognate ligand of the orphan G protein-coupled receptor FM-3. J. Biol. Chem.275 (28): 21068-74. [PMID:10783389]

8. Fukue Y, Sato T, Teranishi H, Hanada R, Takahashi T, Nakashima Y, Kojima M. (2006) Regulation of gonadotropin secretion and puberty onset by neuromedin U. FEBS Lett.580 (14): 3485-8. [PMID:16716306]

9. Funes S, Hedrick JA, Yang S, Shan L, Bayne M, Monsma FJ Jr, Gustafson EL. (2002) Cloning and characterization of murine neuromedin U receptors. Peptides23: 1607-1615. [PMID:12217421]

10. Gartlon J, Szekeres P, Pullen M, Sarau HM, Aiyar N, Shabon U, Michalovich D, Steplewski K, Ellis C, Elshourbagy N et al.. (2004) Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats. Psychopharmacology (Berl.)177 (1-2): 1-14. [PMID:15205870]

11. Graham ES, Littlewood P, Turnbull Y, Mercer JG, Morgan PJ, Barrett P. (2005) Neuromedin-U is regulated by the circadian clock in the SCN of the mouse. Eur. J. Neurosci.21 (3): 814-9. [PMID:15733101]

12. Graham ES, Turnbull Y, Fotheringham P, Nilaweera K, Mercer JG, Morgan PJ, Barrett P. (2003) Neuromedin U and Neuromedin U receptor-2 expression in the mouse and rat hypothalamus: effects of nutritional status. J. Neurochem.87: 1165-1173. [PMID:14622096]

13. Guan XM, Yu H, Jiang Q, Van Der Ploeg LH, Liu Q. (2001) Distribution of neuromedin U receptor subtype 2 mRNA in the rat brain. Brain Res. Gene Expr. Patterns1 (1): 1-4. [PMID:15018811]

14. Hanada R, Nakazato M, Murakami N, Sakihara S, Yoshimatsu H, Toshinai K, Hanada T, Suda T, Kangawa K, Matsukura S, Sakata T. (2001) A role for neuromedin U in stress response. Biochem. Biophys. Res. Commun.289: 225-228. [PMID:11708803]

15. Hanada R, Teranishi H, Pearson JT, Kurokawa M, Hosoda H, Fukushima N, Fukue Y, Serino R, Fujihara H, Ueta Y et al.. (2004) Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway. Nat. Med.10 (10): 1067-73. [PMID:15448684]

16. Hanada T, Date Y, Shimbara T, Sakihara S, Murakami N, Hayashi Y, Kanai Y, Suda T, Kangawa K, Nakazato M. (2003) Central actions of neuromedin U via corticotropin-releasing hormone. Biochem. Biophys. Res. Commun.311 (4): 954-8. [PMID:14623274]

17. Hosoya M, Moriya T, Kawamata Y, Ohkubo S, Fujii R, Matsui H, Shintani Y, Fukusumi S, Habata Y, Hinuma S, Onda H, Nishimura O, Fujino M. (2000) Identification and functional characterization of a novel subtype of neuromedin U receptor. J. Biol. Chem.275: 29528-29532. [PMID:10887190]

18. Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM, Zeng Z, Williams DL Jr, Feighner SD, Nunes CN, Murphy B, Stair JN, Yu H, Jiang Q, Clements MK, Tan CP, McKee KK, Hreniuk DL, McDonald TP, Lynch KR, Evans JF, Austin CP, Caskey CT, Van der Ploeg LH, Liu Q. (2000) Identification of receptors for neuromedin U and its role in feeding. Nature406: 70-74. [PMID:10894543]

19. Hsu SH, Luo CW. (2007) Molecular dissection of G protein preference using Gsalpha chimeras reveals novel ligand signaling of GPCRs. Am. J. Physiol. Endocrinol. Metab.293 (4): E1021-9. [PMID:17652154]

20. Ivanov TR, Lawrence CB, Stanley PJ, Luckman SM. (2002) Evaluation of neuromedin u actions in energy homeostasis and pituitary function. Endocrinology143: 3813-3821. [PMID:12239092]

21. Jethwa PH, Small CJ, Smith KL, Seth A, Darch SJ, Abbott CR, Murphy KG, Todd JF, Ghatei MA, Bloom SR. (2005) Neuromedin U has a physiological role in the regulation of food intake and partially mediates the effects of leptin. Am. J. Physiol. Endocrinol. Metab.289 (2): E301-5. [PMID:16014357]

22. Jethwa PH, Smith KL, Small CJ, Abbott CR, Darch SJ, Murphy KG, Seth A, Semjonous NM, Patel SR, Todd JF, Ghatei MA, Bloom SR. (2006) Neuromedin U partially mediates leptin-induced hypothalamo-pituitary adrenal (HPA) stimulation and has a physiological role in the regulation of the HPA axis in the rat. Endocrinology147: 2886-2892. [PMID:16556758]

23. Kamisoyama H, Honda K, Saneyasu T, Sugahara K, Hasegawa S. (2007) Central administration of neuromedin U suppresses food intake in chicks. Neurosci. Lett.420 (1): 1-5. [PMID:17445984]

24. Ketterer K, Kong B, Frank D, Giese NA, Bauer A, Hoheisel J, Korc M, Kleeff J, Michalski CW, Friess H. (2009) Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett.277 (1): 72-81. [PMID:19118941]

25. Kojima M, Haruno R, Nakazato M, Date Y, Murakami N, Hanada R, Matsuo H, Kangawa K. (2000) Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). Biochem. Biophys. Res. Commun.276 (2): 435-8. [PMID:11027493]

26. Kowalski TJ, Spar BD, Markowitz L, Maguire M, Golovko A, Yang S, Farley C, Cook JA, Tetzloff G, Hoos L et al.. (2005) Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice. J. Endocrinol.185 (1): 151-64. [PMID:15817836]

27. Liu JJ, Payza K, Huang J, Liu R, Chen T, Coupal M, Laird JM, Cao CQ, Butterworth J, Lapointe S et al.. (2009) Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2. J. Pharmacol. Exp. Ther.330 (1): 268-75. [PMID:19369576]

28. Mori K, Miyazato M, Ida T, Murakami N, Serino R, Ueta Y, Kojima M, Kangawa K. (2005) Identification of neuromedin S and its possible role in the mammalian circadian oscillator system. EMBO J24: 325-335. [PMID:15635449]

29. Nakahara K, Hanada R, Murakami N, Teranishi H, Ohgusu H, Fukushima N, Moriyama M, Ida T, Kangawa K, Kojima M. (2004) The gut-brain peptide neuromedin U is involved in the mammalian circadian oscillator system. Biochem. Biophys. Res. Commun.318 (1): 156-61. [PMID:15110767]

30. Nakahara K, Kojima M, Hanada R, Egi Y, Ida T, Miyazato M, Kangawa K, Murakami N. (2004) Neuromedin U is involved in nociceptive reflexes and adaptation to environmental stimuli in mice. Biochem. Biophys. Res. Commun.323 (2): 615-20. [PMID:15369794]

31. Nakazato M, Hanada R, Murakami N, Date Y, Mondal MS, Kojima M, Yoshimatsu H, Kangawa K, Matsukura S. (2000) Central effects of neuromedin U in the regulation of energy homeostasis. Biochem. Biophys. Res. Commun.277: 191-194. [PMID:11027662]

32. Nandha KA, Benito-Orfila MA, Jamal H, Akinsanya KO, Bloom SR, Smith DM. (1999) Effect of steroids and the estrous cycle on uterine neuromedin U receptor expression. Peptides20: 1203-1209. [PMID:10573292]

33. Niimi M, Murao K, Taminato T. (2001) Central administration of neuromedin U activates neurons in ventrobasal hypothalamus and brainstem. Endocrine16: 201-206. [PMID:11954664]

34. Ozaki Y, Onaka T, Nakazato M, Saito J, Kanemoto K, Matsumoto T, Ueta Y. (2002) Centrally Administered Neuromedin U Activates Neurosecretion and Induction of c-fos Messenger Ribonucleic Acid in the Paraventricular and Supraoptic Nuclei of Rat. Endocrinology143: 4320-4329. [PMID:12399428]

35. Peier A, Kosinski J, Cox-York K, Qian Y, Desai K, Feng Y, Trivedi P, Hastings N, Marsh DJ. (2009) The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2). Endocrinology150 (7): 3101-9. [PMID:19324999]

36. Quan H, Funabashi T, Furuta M, Kimura F. (2003) Effects of neuromedin U on the pulsatile LH secretion in ovariectomized rats in association with feeding conditions. Biochem. Biophys. Res. Commun.311 (3): 721-7. [PMID:14623332]

37. Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, Zhou S, Kouranova EV, Nagorny R, Guevarra MS, Dai M, Lerman GS, Vaysse PJ, Branchek TA, Gerald C, Forray C, Adham N. (2000) Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system. J. Biol. Chem.275: 32452-32459. [PMID:10899166]

38. Rucinski M, Ziolkowska A, Tyczewska M, Szyszka M, Malendowicz LK. (2008) Neuromedin U directly stimulates growth of cultured rat calvarial osteoblast-like cells acting via the NMU receptor 2 isoform. Int. J. Mol. Med.22 (3): 363-8. [PMID:18698496]

39. Sakamoto T, Mori K, Miyazato M, Kangawa K, Sameshima H, Nakahara K, Murakami N. (2008) Involvement of neuromedin S in the oxytocin release response to suckling stimulus. Biochem. Biophys. Res. Commun.375 (1): 49-53. [PMID:18675786]

40. Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, Inose H, Ida T, Mieda M, Takeuchi Y et al.. (2007) Central control of bone remodeling by neuromedin U. Nat. Med.13 (10): 1234-40. [PMID:17873881]

41. Shan L, Qiao X, Crona JH, Behan J, Wang S, Laz T, Bayne M, Gustafson EL, Monsma FJ Jr, Hedrick JA. (2000) Identification of a novel neuromedin U receptor subtype expressed in the central nervous system. J. Biol. Chem.275: 39482-39486. [PMID:11010960]

42. Szekeres PG, Muir AI, Spinage LD, Miller JE, Butler SI, Smith A, Rennie GI, Murdock PR, Fitzgerald LR, Wu H, McMillan LJ, Guerrera S, Vawter L, Elshourbagy NA, Mooney JL, Bergsma DJ, Wilson S, Chambers JK. (2000) Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3. J. Biol. Chem.275: 20247-20250. [PMID:10811630]

43. Thompson EL, Murphy KG, Todd JF, Martin NM, Small CJ, Ghatei MA, Bloom SR. (2004) Chronic administration of NMU into the paraventricular nucleus stimulates the HPA axis but does not influence food intake or body weight. Biochem. Biophys. Res. Commun.323 (1): 65-71. [PMID:15351702]

44. Torres R, Croll SD, Vercollone J, Reinhardt J, Griffiths J, Zabski S, Anderson KD, Adams NC, Gowen L, Sleeman MW et al.. (2007) Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responses. Pain130 (3): 267-78. [PMID:17379411]

45. Trejter M, Neri G, Rucinski M, Majchrzak M, Nussdorfer GG, Malendowicz LK. (2008) Neuromedin-U stimulates enucleation-induced adrenocortical regeneration in the rat. Int. J. Mol. Med.21 (6): 683-7. [PMID:18506360]

46. Vigo E, Roa J, López M, Castellano JM, Fernandez-Fernandez R, Navarro VM, Pineda R, Aguilar E, Diéguez C, Pinilla L et al.. (2007) Neuromedin s as novel putative regulator of luteinizing hormone secretion. Endocrinology148 (2): 813-23. [PMID:17110433]

47. Wren AM, Small CJ, Abbott CR, Jethwa PH, Kennedy AR, Murphy KG, Stanley SA, Zollner AN, Ghatei MA, Bloom SR. (2002) Hypothalamic actions of neuromedin U. Endocrinology143: 4227-4234. [PMID:12399416]

48. Yang G, Su J, Yao Y, Lei Z, Zhang G, Li X. (2010) The regulatory mechanism of neuromedin S on luteinizing hormone in pigs. Anim. Reprod. Sci.122 (3-4): 367-74. [PMID:21071159]

49. Yu XH, Cao CQ, Mennicken F, Puma C, Dray A, O'Donnell D, Ahmad S, Perkins M. (2003) Pro-nociceptive effects of neuromedin U in rat. Neuroscience120: 467-474. [PMID:12890516]

50. Zeng H, Gragerov A, Hohmann JG, Pavlova MN, Schimpf BA, Xu H, Wu LJ, Toyoda H, Zhao MG, Rohde AD et al.. (2006) Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding. Mol. Cell. Biol.26 (24): 9352-63. [PMID:17030627]

51. Ziolkowska A, Macchi C, Trejter M, Rucinski M, Nowak M, Nussdorfer GG, Malendowicz LK. (2008) Effects of neuromedin-U on immature rat adrenocortical cells: in vitro and in vivo studies. Int. J. Mol. Med.21 (3): 303-7. [PMID:18288377]

To cite this database page, please use the following:

Gary B. Willars, Khaled Al-hosaini.
Neuromedin U receptors: NMU2 receptor. Last modified on 04/03/2013. Accessed on 28/07/2014. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=299.

Contact us | Print | Back to top | Help
Copyright © 2014 IUPHAR